In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...

Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...

But COVID-19 tends to jump in the winter months ... The Pfizer and Moderna shots are formulated against a virus subtype ...

People reporting long-COVID symptoms had elevated levels of cytokines ... The FDA concluded that the event was not related to ...

China has reported seven more H9N2 avian flu infections in humans, mostly involving children and all in people whose symptoms ...

2024 Healthcare & Pharmaceuticalscategory Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales November 12, 2024 Healthcare & Pharmaceuticalscategory AstraZeneca lifts 2024 ...

It's about trust. And Novavax hopes to be among the first companies to commercialise a combination vaccine (COVID and influenza). “That's almost the holy grail, right?” she said.

Among other movers, Biotech firm Novavax dropped 6% after cutting its annual revenue forecast due to lower-than-expected ...

Biotech firm Novavax dropped 9.1% after cutting its annual revenue forecast due to lower-than-expected sales of its COVID-19 ...